1. Could CYDY use the commercialization company to go it alone for mTNBC and make CYDY a very valuable company? I guess the answer depends on the upfront payments for HIV and possibly NASH pending results. IMO, CYDY needs to chase at least one indication to bring in straight revenue to make CYDY a lasting name and to make investors a great profit.
2. $35 billion/year and an estimated $60B/year in 2028 is an insane amount of revenue. I hope that CYDY will fight for a decent percentage of the NASH sales during licensing discussion (pending good results), but that may be difficult with results only based on animal studies.